John F. DiPersio

Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data.

The results demonstrate the importance of continuous patient monitoring and management during CAR-T therapy and demonstrate an evolving treatment landscape, including more aggressive management of CRS and interest in preventive therapies for CRS and ICANS.